Original articleHidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis
Section snippets
Methods
This was a retrospective, matched case-control study. After protocol approval by the Partners Healthcare Human Research Committee, the Research Patient Data Registry (RPDR) at Massachusetts General Hospital was queried to identify all patients who received at least 1 ICD-9 code for HS (705.83) between January 1, 1980, and October 1, 2013. The medical records of all returned cases were manually reviewed using the Massachusetts General Hospital electronic medical record and Queriable Patient
Results
Our initial RPDR query of all patients who received at least 1 ICD-9 code of 705.83 between January 1, 1980, and October 1, 2013, yielded 2292 potential cases. A complete chart review resulted in 1776 verified cases of HS and a positive predictive value of 77% (1776/2292) for the code of 705.83 in predicting HS in this population. When compared with the entire population of Massachusetts General Hospital patients within RPDR, the prevalence of HS was 0.078% (1776/2,279,254). The mean age (SD)
Discussion
In this study, we used chart-verified patients who received at least 1 ICD-9 code for HS within a large, electronic medical record database, yielding an overall prevalence of 0.078% of HS within this population. Our prevalence is consistent with other reports of claims-based data in the United States but lower than results from European studies, which relied on patient self-report and estimated prevalence rates between 1% and 4%.3, 4, 5, 6 With a prevalence of only 78 per 100,000 our data
References (46)
- et al.
Hidradenitis suppurativa
Dermatol Clin
(2010) - et al.
Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States
J Am Acad Dermatol
(2013) - et al.
The prevalence of hidradenitis suppurativa and its potential precursor lesions
J Am Acad Dermatol
(1996) - et al.
Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies
J Am Acad Dermatol
(2008) - et al.
The prevalence of metabolic syndrome in patients with hidradenitis suppurativa
J Am Acad Dermatol
(2014) - et al.
Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity
J Am Acad Dermatol
(2009) - et al.
Hidradenitis suppurativa: a comprehensive review
J Am Acad Dermatol
(2009) - et al.
Disease concomitance in psoriasis
J Am Acad Dermatol
(1995) - et al.
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
J Am Acad Dermatol
(2011) - et al.
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial
J Am Acad Dermatol
(2010)
The risk of lymphoma in patients with psoriasis
J Invest Dermatol
Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases
J Am Acad Dermatol
The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands
Br J Dermatol
Epidemiology
Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity
Br J Dermatol
Increased prevalence of metabolic syndrome in patients with acne inversa
PLoS One
Hidradenitis suppurativa and squamous cell carcinoma
Dermatol Surg
The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease
Br J Dermatol
Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy
J Cutan Med Surg
The validity of the diagnostic code for hidradenitis suppurativa in an electronic database
Br J Dermatol
Clinical practice: hidradenitis suppurativa
N Engl J Med
Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial
Ann Intern Med
Cited by (0)
Dr Shlyankevich has partial fellowship funding from Janssen.
Disclosure: Dr Kimball has served as an investigator and consultant for Abbvie. Dr Shlyankevich has partial fellowship funding from Janssen. Ms Chen and Ms Kim have no conflicts of interest to declare.